The US Food and Drug Administration has approved xanomeline and trospium chloride capsules for the treatment of schizophrenia in adults. This marks the first antipsychotic medication that targets cholinergic receptors rather than dopamine receptors, which have been the standard approach for schizophrenia. It also offers patients a novel alternative to existing antipsychotic drugs. Schizophrenia is a serious and chronic mental illness affecting approximately 1% of Americans, contributing to significant disability worldwide.
The condition can lead to hallucinations, cognitive difficulties, and social impairments. Clinical Trials The effectiveness of xanomeline and trospium chloride for treating schizophrenia in adults was assessed in two similar studies. These studies were randomized, double-blind, placebo-controlled, and conducted at multiple centers. Participants were diagnosed with…
